These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27563256)

  • 1. Adherence to a flexible extended regimen for oral hormonal contraception provided in blister packaging compared with an adherence-supporting digital tablet dispenser: historical comparison of data from two clinical studies.
    Elliesen J; Trummer D
    Int J Womens Health; 2016; 8():351-6. PubMed ID: 27563256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study.
    Wiegratz I; Elliesen J; Paoletti AM; Walzer A; Kirsch B
    Int J Womens Health; 2015; 7():19-29. PubMed ID: 25609999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptive use and protective behavior after missed pills.
    Oakley D; Potter L; de Leon-Wong E; Visness C
    Fam Plann Perspect; 1997; 29(6):277-9, 287. PubMed ID: 9429874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
    Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H
    Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
    Jensen JT; Garie SG; Trummer D; Elliesen J
    Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using daily text-message reminders to improve adherence with oral contraceptives: a randomized controlled trial.
    Hou MY; Hurwitz S; Kavanagh E; Fortin J; Goldberg AB
    Obstet Gynecol; 2010 Sep; 116(3):633-640. PubMed ID: 20733446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Oral Contraceptive Adherence and Pregnancy Rates.
    Creinin MD; Jensen JT; Chen MJ; Black A; Costescu D; Foidart JM
    Obstet Gynecol; 2023 May; 141(5):989-994. PubMed ID: 37023457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study.
    Momoeda M; Kondo M; Elliesen J; Yasuda M; Yamamoto S; Harada T
    Int J Womens Health; 2017; 9():295-305. PubMed ID: 28496369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Gerlinger C; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observational study of adherence to combined oral contraceptive regimens.
    Bastianelli C; Farris M; Bruno Vecchio RC; Rosato E; Guida M; Benagiano G
    Gynecol Endocrinol; 2017 Feb; 33(2):168-172. PubMed ID: 27809677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring Patient Adherence to Malaria Treatment: A Comparison of Results from Self-Report and a Customised Electronic Monitoring Device.
    Bruxvoort K; Festo C; Cairns M; Kalolella A; Mayaya F; Kachur SP; Schellenberg D; Goodman C
    PLoS One; 2015; 10(7):e0134275. PubMed ID: 26214848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a Digital Medication Management System for Effective Assessment and Enhancement of Patient Adherence to Therapy (ReX): Feasibility Study.
    Shtrichman R; Conrad S; Schimo K; Shachar R; Machluf E; Mindal E; Epstein H; Epstein S; Paz A
    JMIR Hum Factors; 2018 Nov; 5(4):e10128. PubMed ID: 30478020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadriphasic versus monophasic oral contraceptives for contraception.
    Van Vliet HA; Raps M; Lopez LM; Helmerhorst FM
    Cochrane Database Syst Rev; 2011 Nov; (11):CD009038. PubMed ID: 22071862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. User characteristics and oral contraceptive compliance in Egypt.
    Trottier DA; Potter LS; Taylor BA; Glover LH
    Stud Fam Plann; 1994; 25(5):284-92. PubMed ID: 7871553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study.
    Anthuber S; Schramm GA; Heskamp ML
    Clin Drug Investig; 2010; 30(4):211-20. PubMed ID: 20225905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient understanding of oral contraceptive pill instructions related to missed pills: a systematic review.
    Zapata LB; Steenland MW; Brahmi D; Marchbanks PA; Curtis KM
    Contraception; 2013 May; 87(5):674-84. PubMed ID: 23040136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake.
    Duijkers IJM; Heger-Mahn D; Drouin D; Colli E; Skouby S
    Contraception; 2016 Apr; 93(4):303-309. PubMed ID: 26708301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen).
    Bitzer J; Banal-Silao MJ; Ahrendt HJ; Restrepo J; Hardtke M; Wissinger-Graefenhahn U; Trummer D
    Int J Womens Health; 2015; 7():501-9. PubMed ID: 26056491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.